NFSG
LTRN icon

Newbridge Financial Services Group’s Lantern Pharma LTRN Stock Holding History

Newbridge Financial Services Group’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200
Closed -$632 – 1343
2025
Q2 		$632 Buy
+200
New +$675 ﹤0.01% 1231

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Newbridge Financial Services Group's LTRN Position: Q3 2025 in Review

Newbridge Financial Services Group sold out of Lantern Pharma (LTRN) in Q3 2025, closing a stake of 200 shares — an estimated $632 sold.

Newbridge Financial Services Group first reported a position in LTRN in Q2 2025 and held it in 1 quarter. The position peaked at $632 in Q2 2025. 30 funds tracked by Wall St. Rank hold LTRN as of Q3 2025.

  • Newbridge Financial Services Group reported no remaining Lantern Pharma position as of Q3 2025 after selling out during the quarter.
  • Newbridge Financial Services Group sold 200 Lantern Pharma shares in Q3 2025, an estimated $632.
  • Newbridge Financial Services Group first reported a position in Lantern Pharma in Q2 2025 and held it in 1 quarter.
  • Newbridge Financial Services Group's Lantern Pharma position peaked at $632 in Q2 2025.
  • 30 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2025.

Based on Newbridge Financial Services Group's 13F filing for Q3 2025, filed 13 Nov 2025.